You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Antibodies (CDKN2A)
On are 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies from different suppliers available. A total of 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) products are currently listed.
ARF, ARF-INK4a, CDK4I, CDKN2, CMM2, INK4, INK4A, INK4a-ARF, Ink4a/Arf, MLM, MTS-1, MTS1, P14, P14ARF, P16, p16(INK4a), P16-INK4A, p16Cdkn2a, P16INK4, p16INK4a, P19, p19, P19ARF, Pctr1, TP16
list all antibodies Gene Name GeneID UniProt
Anti-Rat CDKN2A CDKN2A 25163 Q9R0Z3
Anti-Human CDKN2A CDKN2A 1029 P42771 , Q8N726
Anti-Mouse CDKN2A CDKN2A 12578 P51480 , Q64364

Show all synonyms

More Antibodies against Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. Oropharyngeal, p16INK4-immunolabelled tumors showed an improved disease-specific survival compared to the non-p16INK4-immunolabelled group.

  2. Study found that Fbl12 (show FBXL12 Antibodies) binds and ubiquitinates p21 (show CDKN1A Antibodies) which allows its stability. In addition, Fbl12 (show FBXL12 Antibodies) regulates default degradation under basal conditions but not under UV-stimulated conditions. These findings elucidate novel mechanisms that underlie the regulation of p21 (show CDKN1A Antibodies) expression level in cells.

  3. Loss of heterozygosity of TP53 (show TP53 Antibodies), P16, SMAD4 (show SMAD4 Antibodies) and APC (show APC Antibodies) genes was observed in esophageal adenocarcinoma.

  4. Report immunohistochemical detection of p16 in cervical, vulvar, anal and head and neck neoplasms.

  5. CDKN2A mRNA expression in cervical cancer

  6. These finding suggest p16(INK4a) expression and p14(ARF) expression may play an important role in the progression of proliferative breast tissue to invasive cancer, and may be useful as prognostic factors

  7. We conducted a meta-analysis to examine p16INK4a expression in uterine smooth muscle tumors. p16INK4a expression was significantly higher in leiomyosarcoma than in leiomyoma variants or smooth muscle tumors of uncertain malignant potential. There was a significant correlation between overexpressed p16INK4a and recurrence rates of uterine smooth muscle tumors

  8. p16 immunostaining and high-risk human papillomavirus (HR-HPV) RNA in situ hybridization can be employed as useful ancillary tools in differentiating between noninvasive and invasive adenoid basal tumors along with careful histopathologic evaluation.

  9. High methylation in the p16 promoter region is associated with lung cancer.

  10. In head and neck squamous cell carcinoma, p16 expression was associated with a lymphocytic T-cytotoxic response. neither p16 nor p53 (show TP53 Antibodies) expression were associated with prognosis. p16 and p53 (show TP53 Antibodies) expression are associated with the histological subtype and the T stage even in non-oropharyngeal-restricted tumours.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. deletion of the Cdkn2a gene in p53 (show TP53 Antibodies)(R172H) -induced SCCs promoted a dramatic increase in metastasis rates and a shorter survival in mice that developed these tumours, compared with those observed in mice with tumours in which Cdkn2a was deleted in the presence of a p53 (show TP53 Antibodies) loss-of-function mutation or wild-type p53 (show TP53 Antibodies).

  2. loss of Brca1 (show BRCA1 Antibodies), a tumor suppressor that functions in DNA damage repair, in the mammary epithelium induced senescence with induction of p16 and a decline of stem cell function, which was rescued by p16 loss.

  3. TWIST1 (show TWIST1 Antibodies)-E protein heterodimeric complexes may thus constitute the main active forms of TWIST1 (show TWIST1 Antibodies) with regard to senescence inhibition over the time course of breast tumorigenesis.

  4. AMPKalpha2 (show PRKAA2 Antibodies) isoform plays a fundamental role in anti-oxidant stress and anti-senescence

  5. that MEK (show MDK Antibodies) activity induced cell cycle arrest through accumulation of p16/19(cdkn2a)

  6. Data indicate the cyclin-dependent kinase inhibitor 2A (p19Arf) and interferon beta (IFN-beta (show IFNB1 Antibodies)) combination as a cancer immunotherapy strategy.

  7. Our findings reveal a novel role for p16(Ink4a) and cellular senescence in promoting insulin (show INS Antibodies) secretion by beta cells and in regulating normal functional tissue maturation with age.

  8. Loss of Nf2 (show NF2 Antibodies) and Cdkn2a/b have synergistic effects with PDGF-B (show PDGFB Antibodies) overexpression promoting meningioma malignant transformation.

  9. Inactivation of INK4a and ARF induces myocardial proliferation and improves cardiac repair following ischemiareperfusion

  10. loss of p19ARF overcomes senescence of LSECs, allowing immortalization of cells without losing endothelial characteristics.

Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antigen Profile

Antigen Summary

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Alternative names and synonyms associated with Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A)

  • cyclin-dependent kinase inhibitor 2A (Cdkn2a) antibody
  • cyclin-dependent kinase inhibitor 2A (LOC100340625) antibody
  • cyclin-dependent kinase inhibitor 2A (CDKN2A) antibody
  • ARF antibody
  • ARF-INK4a antibody
  • CDK4I antibody
  • CDKN2 antibody
  • CMM2 antibody
  • INK4 antibody
  • INK4A antibody
  • INK4a-ARF antibody
  • Ink4a/Arf antibody
  • MLM antibody
  • MTS-1 antibody
  • MTS1 antibody
  • P14 antibody
  • P14ARF antibody
  • P16 antibody
  • p16(INK4a) antibody
  • P16-INK4A antibody
  • p16Cdkn2a antibody
  • P16INK4 antibody
  • p16INK4a antibody
  • P19 antibody
  • p19 antibody
  • P19ARF antibody
  • Pctr1 antibody
  • TP16 antibody

Protein level used designations for CDKN2A

CDK4I , Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4) , cell cycle inhibitor , cell cycle regulator , cyclin-dependent kinase 4 inhibitor A , cyclin-dependent kinase inhibitor 2a p16Ink4a , cyclin-dependent kinase inhibitor 2a p19Arf , p16-INK4 , p16-INK4a , CDK4 inhibitor p16-INK4 , cell cycle negative regulator beta , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , multiple tumor suppressor 1 , cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2A, isoforms 1/2 , cyclin-dependent kinase inhibitor protein , mitochondrial smARF

25163 Rattus norvegicus
100731972 Cavia porcellus
100340625 Oryctolagus cuniculus
1029 Homo sapiens
12578 Mus musculus
Did you look for something else?